Japan Drug Pricing and NHI Reform: Annual Tracker | Policy & Market Intelligence

Description

List of Tables

Japan is the world's third-largest pharmaceutical market, and its National Health Insurance system sets the price of nearly every drug sold there. The NHI pricing system is not a negotiation but a rules engine: formulas for new drugs, scheduled revisions that reprice the entire market, and special mechanisms - cost-effectiveness assessment, market-expansion repricing, the long-listed product rules - that can cut a product's price years after launch. The FY2026 reform continued the tightening trajectory, applying the first G1-rule cuts to originator biologics and adjusting the cost-effectiveness assessment framework, and the Ministry of Finance has already signaled its FY2027 agenda. For any company with revenue in Japan, the pricing system is the single largest policy exposure.

The tension is between two documented problems pulling in opposite directions. One is "drug loss" and "drug lag": products launched elsewhere but never, or late, in Japan, a gap the government is actively trying to close with incentives and expedited pathways. The other is fiscal: an aging population and a strained insurance budget create permanent downward pressure on prices, and every reform cycle finds new categories to squeeze - this time originator biologics whose patents have expired. Innovators argue that aggressive repricing causes the very drug loss the government deplores; payers respond that Japan still pays more than comparable systems for mature products. Each annual revision and each mid-cycle repricing is a round in this argument, and the rules shift a little every time.

This annual tracker explains the system and records the changes. It lays out the NHI pricing architecture - new drug pricing methods, the biannual and mid-year revision mechanics, the special repricing rules, and the cost-effectiveness assessment system - then documents the FY2026 reform package in detail and tracks the FY2027 agenda as it forms. Product-level sections examine how the rules touch major franchises, including repricing precedents for products such as Opdivo and Keytruda and cost-effectiveness cases such as Leqembi. The tracker answers what changed, which products and companies are exposed, and what to watch next.

The report is written for pharmaceutical market access and pricing teams, investors modeling Japanese revenue, market-entry planners sizing the opportunity, and policy affairs professionals. It is used as a system reference, a reform tracker, and an exposure screen, with quarterly updates and a full annual edition.

Scope and Coverage: The tracker covers the NHI drug pricing system, the FY2026 reform and its implementation, the FY2027 agenda, cost-effectiveness assessment, and special repricing mechanisms, with product-level exposure documentation through 2026.

Report Highlights:

Complete explanation of NHI pricing architecture for new and listed drugs
FY2026 reform documentation, including the first G1 cuts on originator biologics
Cost-effectiveness assessment system mechanics and selected product cases
Market-expansion and special repricing precedents, including Opdivo and Keytruda cases
FY2027 agenda tracking with Ministry of Finance positions
Company-level exposure profiles across Japanese majors and foreign multinationals

Product Code: JPH-091

Table of Content

1. Executive Summary

2. Japan Drug Pricing and NHI Reform: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

Takeda (JP) - Japanese pharma major; repricing exposure across GI and oncology
Daiichi Sankyo (JP) - oncology franchise subject to market-expansion repricing
Astellas (JP) - repricing and long-listed product exposure
Chugai (JP) - Roche subsidiary with biologics pricing exposure
Ono Pharmaceutical (JP) - Opdivo lifecycle pricing precedent
Eisai (JP) - CEA-applied products including Leqembi
Otsuka (JP) - psychiatric and nephrology franchise pricing
Pfizer (US) - foreign major with a large Japan portfolio
Novartis (CH) - CEA and repricing exposure
AstraZeneca (UK) - oncology and respiratory repricing exposure
Eli Lilly (US) - Mounjaro pricing and GLP-1 category formation
MSD/Merck & Co (US) - Keytruda repricing precedent cases

Product Code: JPH-091

List of Tables

Table 1. NHI system structure: insurers, providers, and the pricing role of the state
Table 2. Chuikyo council structure and reform decision process
Table 3. New drug pricing methods: comparator and cost-calculation routes
Table 4. Premium categories in new drug pricing: innovation, usefulness, and marketability
Table 5. Sakigake and orphan premiums in price setting
Table 6. Foreign price reference rule and its application
Table 7. Scheduled NHI revision mechanics: the biannual cycle
Table 8. Mid-year repricing practice and its expansion
Table 9. Market-expansion repricing rule: triggers and method
Table 10. Special repricing rules for long-listed products
Table 11. G1 rule structure and its FY2026 application to originator biologics
Table 12. Cost-effectiveness assessment system: design and thresholds
Table 13. Products selected for cost-effectiveness assessment since 2019
Table 14. Leqembi cost-effectiveness assessment case
Table 15. Opdivo market-expansion repricing precedent
Table 16. Keytruda repricing precedent cases
Table 17. FY2026 reform package: full documentation
Table 18. FY2026 price list changes by category
Table 19. Ministry of Finance positions on FY2027 reform
Table 20. Pharmaceutical industry association positions on FY2027
Table 21. Drug lag and drug loss metrics and government responses
Table 22. Measures to address drug loss: pricing incentives and pathways
Table 23. Generic and biosimilar price setting rules
Table 24. Biosimilar uptake incentives in the NHI system
Table 25. Generic substitution policy and pharmacy incentives
Table 26. Long-listed product policy and unprofitable drug repricing
Table 27. Pediatric and orphan drug pricing provisions
Table 28. Regenerative medicine and cell therapy pricing precedents
Table 29. Companion diagnostic reimbursement mechanics
Table 30. Medical device pricing system contrast with drugs
Table 31. NHI price revision impact assessment method (framework)
Table 32. Takeda repricing exposure across GI and oncology
Table 33. Daiichi Sankyo oncology franchise repricing exposure
Table 34. Astellas repricing and long-listed product exposure
Table 35. Chugai biologics pricing exposure
Table 36. Ono Pharmaceutical Opdivo lifecycle pricing
Table 37. Eisai cost-effectiveness exposure including Leqembi
Table 38. Otsuka psychiatric and nephrology franchise pricing
Table 39. Pfizer Japan portfolio pricing exposure
Table 40. Novartis cost-effectiveness and repricing exposure
Table 41. AstraZeneca oncology and respiratory repricing exposure
Table 42. Eli Lilly Mounjaro pricing and GLP-1 category formation
Table 43. MSD Keytruda repricing exposure
Table 44. Other foreign major exposure profiles
Table 45. Distributor and wholesaler margin mechanics in the NHI system
Table 46. Pharmacy reimbursement and dispensing fee interaction
Table 47. Hospital purchasing practice under NHI prices
Table 48. Reform scenario analysis for FY2027
Table 49. Pricing exposure screening method for portfolios
Table 50. Annual reform calendar and monitoring protocol

List of Figures

Figure 1. NHI system structure diagram
Figure 2. Chuikyo decision process flow
Figure 3. New drug pricing decision tree
Figure 4. Premium category structure in price setting
Figure 5. Foreign price reference calculation flow
Figure 6. Biannual revision mechanics flow
Figure 7. Mid-year repricing timeline
Figure 8. Market-expansion repricing trigger logic
Figure 9. Long-listed product repricing rule map
Figure 10. G1 rule application flow for originator biologics
Figure 11. Cost-effectiveness assessment workflow
Figure 12. Cost-effectiveness selected product timeline since 2019
Figure 13. Leqembi assessment case timeline
Figure 14. Opdivo repricing precedent timeline
Figure 15. Keytruda repricing precedent timeline
Figure 16. FY2026 reform package component map
Figure 17. FY2026 category change map
Figure 18. Ministry of Finance FY2027 position map
Figure 19. Industry association FY2027 position map
Figure 20. Drug lag and drug loss measurement framework
Figure 21. Drug loss countermeasure map
Figure 22. Generic and biosimilar price setting flow
Figure 23. Biosimilar incentive structure map
Figure 24. Generic substitution policy map
Figure 25. Unprofitable drug repricing mechanism
Figure 26. Pediatric and orphan pricing provision map
Figure 27. Regenerative medicine pricing precedent timeline
Figure 28. Companion diagnostic reimbursement flow
Figure 29. Device versus drug pricing system comparison
Figure 30. Revision impact assessment workflow
Figure 31. Takeda exposure map by franchise
Figure 32. Daiichi Sankyo exposure map
Figure 33. Astellas exposure map
Figure 34. Chugai exposure map
Figure 35. Ono Opdivo lifecycle pricing map
Figure 36. Eisai exposure map
Figure 37. Otsuka exposure map
Figure 38. Pfizer Japan exposure map
Figure 39. Novartis exposure map
Figure 40. AstraZeneca exposure map
Figure 41. Eli Lilly GLP-1 pricing map
Figure 42. MSD Keytruda exposure map
Figure 43. Wholesaler margin mechanics diagram
Figure 44. Pharmacy reimbursement interaction map
Figure 45. Hospital purchasing behavior map under NHI prices
Figure 46. FY2027 reform scenario tree
Figure 47. Portfolio exposure screening flow
Figure 48. Reform calendar and monitoring timeline
Figure 49. Company exposure comparison matrix
Figure 50. Report methodology and source map

Japan Drug Pricing and NHI Reform: Annual Tracker | Policy & Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Japan Drug Pricing and NHI Reform: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures